Advances in the targeted therapy for chronic lymphocytic leukemia in the 54th ASH annual meeting / 白血病·淋巴瘤

ABSTRACT

Recognition has been achieved in the molecular targeting of several key signaling transduction pathways governing cell survival and proliferation in chronic lymphocytic leukemia (CLL).A milestone in CLL treatment is reached.This review provides a brief summary of the 54th ASH annual meeting,focusing on recent advances in the preclinical and clinical investigation of promising target-directed therapeutic agents.